Waleed Al-Darzi, MD
Advanced Heart Failure and Transplant Cardiology · Detroit, MINPI 1164816476
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Lexicon Pharmaceuticals, Inc. at 36.1% of the total. Reporting peaked in 2024 at $4,562 and has fallen 74.5% since, to $1,162 in 2025.
Across 100 payments — averaging $107.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$4K
- Abbott$4K
- AstraZeneca$638
- Amgen$546
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$278
- Abiomed$234
- plus $2K from 19 others
What the payments were for
- Consulting fees$3,83436%
- Travel & lodging$1,25612%
- Food & beverage$5,24249%
- Education$3994%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lexicon Pharmaceuticals, Inc. | 3 | $3,875 |
| Abbott | 30 | $3,591 |
| AstraZeneca | 12 | $638 |
| Amgen | 6 | $546 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $278 |
| Abiomed | 3 | $234 |
| Merck | 10 | $225 |
| Johnson & Johnson | 4 | $170 |
| Procyrion, Inc. | 3 | $129 |
| Terumo Medical Corporation | 1 | $125 |
| Impulse Dynamics (USA) Inc. | 1 | $124 |
| Pfizer | 3 | $124 |
| Kestra Medical Technology Services, Inc. | 1 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Cardiovascular Systems Inc. | 1 | $96 |
| Actelion Pharmaceuticals US, Inc. | 2 | $76 |
| Boston Scientific | 1 | $66 |
| Boehringer Ingelheim | 2 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $34 |
| Mylan Inc. | 1 | $34 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Edwards Lifesciences | 1 | $23 |
| Novo Nordisk | 1 | $19 |
| Medtronic | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,389
- WAINUA$367
- HeartMate 3 Left Ventricular Assist Device$334
- Repatha$260
- OPTIMIZER$248
- LifeVest$225
- ENSITE PRECISION$151
- ANDEXXA$125
- Azur CX Detachable$125
- XARELTO$121
- Assure WCD$119
- CARDIOMEMS$109
How this compares
$10,731 in reported general payments places this provider in the 70th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 178 | $185,326 |
| EliquisApixaban | 169 | $180,176 |
| EntrestoSacubitril/Valsartan | 148 | $157,138 |
| FarxigaDapagliflozin Propanediol | 99 | $72,521 |
| XareltoRivaroxaban | 35 | $41,420 |
| Amiodarone Hcl | 73 | $4,749 |
| Metoprolol Succinate | 223 | $3,826 |
| Atorvastatin Calcium | 200 | $3,106 |
| Spironolactone | 312 | $2,735 |
| Bumetanide | 74 | $2,299 |
| Rosuvastatin Calcium | 146 | $2,073 |
| Ezetimibe | 95 | $1,928 |
| Losartan Potassium | 160 | $1,854 |
| Tacrolimus | 12 | $1,794 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 88 | $1,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $46 | $185,326178 claims |
| PfizerEliquis | $124 | $180,176169 claims |
| NovartisEntresto | $15 | $157,138148 claims |
| AstraZenecaFarxiga | $638 | $72,52199 claims |
| Johnson & JohnsonXarelto | $170 | $41,42035 claims |
| Mylan Inc.Atorvastatin Calcium | $34 | $3,106200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Detroit
- Jennifer CowgerDetroit$165K
- Gillian GraftonDetroit$8K
- Yelena SelektorDetroit$2K
- David FerminGrand Rapids$105K
- Michael DickinsonGrand Rapids$80K
- Thomas CascinoAnn Arbor$39K
- Sangjin LeeGrand Rapids$25K
- Matthew GonzalezGrand Rapids$22K
- Keith AaronsonAnn Arbor$22K
- Abbas BitarAnn Arbor$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.